Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
Lakewood-Amedex announced positive preclinical data for its Bisphosphocin compounds in urinary tract and pulmonary infection animal models. Intravesical Nu-8 achieved up to 97% inhibition of E. coli growth versus no effect in vehicle controls, and aerosolized Bisphosphocins showed in vivo activity against Acinetobacter, P. aeruginosa, and A.
Key figures
- Drug Name
- Nu-8 (Bisphosphocin class)
- Phase Of Trial
- Preclinical (Nu-3 lead candidate in Phase 2a)
- Nu3 topline data
- Q1 2027
- E coli growth inhibition
- up to 97% (10% solution, intravesical, rodent UTI model)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.